Three great stories from STAT that are worth your time this weekend
Eros Dervishi for STAT Millions of Americans want to quit smoking. Critics say drugmakers and the FDA are failing them Drugmakers have largely written off the expensive and time-consuming work of investigating new ways to treat nicotine addiction, for fear that the eventual product wouldn't be profitable enough to warrant the effort. Read more. By Nicholas Florko |
|
Courtesy Akeso Exclusive: The little-known Chinese biotech whose cancer drug beat Keytruda has global ambitions Recent headlines about a potent new immunotherapy have mostly focused on the U.S. company helping to develop it. Less attention has been paid to Akeso, a Chinese biotech that had kept a low profile until its drug bested Merck's mega-blockbuster Keytruda in a late-stage lung cancer trial. Read more. By Jonathan Wosen Jeff Pachoud/AFP via Getty Images Can MRIs ensure prostate cancer screening does more good than harm? A new study showed that using MRI scans can reduce unnecessary diagnosis and treatment of screen-detected prostate cancer by more than half. Experts believe this research could be the "last piece of the puzzle" for rethinking prostate cancer screening guidelines. Read more. By Angus Chen In case you missed it... |
|
Check out more exclusive coverage with a STAT+ subscription | Read premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles. |
|
| STAT, 1 Exchange Place, Boston, MA | ©2024, All Rights Reserved. | |
|
No comments